Samsung Biologics Co Ltd (207940) Stock Price & News

207940:KRX

Samsung Biologics Co Ltd

₩1,398,000.00

+0.14%

(+2,000.00) 1D

Sep 18, 3:30:03 PM GMT+9 · KRW

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Generating top insights for 207940...

Open

₩1,407,000

High

₩1,414,000

Low

₩1,386,000

Mkt. cap

64.71T

Avg. vol.

44.24K

Volume

32.51K

P/E ratio

30.23

52-wk high

₩1,987,000

52-wk low

₩982,000

EPS

₩46,253

Shares outstanding

46.29M

No. of employees

Open

₩1,407,000

High

₩1,414,000

Low

₩1,386,000

Mkt. cap

64.71T

Avg. vol.

44.24K

Volume

32.51K

P/E ratio

30.23

52-wk high

₩1,987,000

52-wk low

₩982,000

EPS

₩46,253

Shares outstanding

46.29M

No. of employees

Related stocks

005930

Samsung Electronics Co Ltd

Samsung Electro-Mechanics Co Ltd

Profile

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines. The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia

About Samsung Biologics Co Ltd

CEOJohn Rim

Employees5.33K

Founded2011

Headquarters-

SectorHealth care

Websitesamsungbiologics.com

All values in KRW	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	1.66T	1.29T	1.26T	1.32T
Cost of goods sold	685.41B	614.00B	578.27B	622.58B
Cost of revenue	685.41B	614.00B	578.27B	622.58B
Research and development expenses	34.28B	-	7.24B	9.03B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	198.01B	144.00B	81.68B	87.90B
Operating expense	245.96B	144.00B	98.09B	111.89B
Total operating expenses	931.37B	758.00B	676.37B	734.47B
Operating income	728.85B	528.00B	580.75B	586.44B
Other non operating income	4.54B	47.00B	2.44B	8.00B
EBT including unusual items	767.00B	575.00B	640.59B	584.63B
EBT excluding unusual items	767.42B	575.00B	640.59B	585.31B
Income tax expense	192.54B	122.00B	171.35B	153.97B
Effective tax rate	25.10%	21.22%	26.75%	26.34%
Other operating expenses	597.95M	-	578.26M	5.68B
Net income	574.46B	510.00B	469.25B	430.65B
Net profit margin	34.60%	39.66%	37.33%	32.60%
Earnings per share	8.07K	8.72K	10.15K	9.31K
Interest and investment income	13.35B	-	13.97B	13.29B
Interest expense	-10.71B	-	-7.15B	-8.78B
Net interest expenses	2.64B	-	6.83B	4.51B
Depreciation and amortization charges	8.84B	-	5.07B	5.26B
EBITDA	907.77B	-	675.31B	698.52B
Gain or loss from assets sale	412.61M	-	18.00K	676.54M

Finance

Ask anything